Abstract
Rare diseases, due to their low prevalence, are often overlooked. However, their economic burden can be very significant in low and middle-income countries due to their high-cost treatment. This scenario poses challenges for the elaboration of health technology assessments due to the quantity and quality of information on these diseases and their therapeutic options. The aim of this scoping review is to map out how the economic evaluations of technologies for the treatment of rare diseases are being carried out, in terms of data sources, methods, perspective of analysis and costs used in Latin America and Southeast Asia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
